Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Panaccione, Remo; Colombel, Jean-Frederic; Travis, Simon; Bossuyt, Peter; Baert, Filip; Vanasek, Tomas; Danalioglu, Ahmet; Novacek, Gottfried; Armuzzi, Alessandro; Reinisch, Walter; Johnson, Scott; Buessing, Marric; Neimark, Ezequiel; Petersson, Joel; Lee, Wan-Ju; D'Haens, Geert

doi:10.1136/gutjnl-2019-318256

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Atıf İçin Kopyala

Panaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., ...Daha Fazla

GUT, cilt.69, sa.4, ss.658-664, 2020 (SCI İndekslerine Giren Dergi)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 69 Konu: 4
Basım Tarihi: 2020
Doi Numarası: 10.1136/gutjnl-2019-318256
Dergi Adı: GUT
Sayfa Sayıları: ss.658-664

Özet

Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn's disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.